Sumitomo Pharma Americainc Smpais A U Spharmaceutical Company That Operates Under Sumitomo Pharma Co Ltd Part Of The Historic Sumitomo Groupestablished In July 2023Smpa Consolidates Seven Former U Saffiliates To Enhance Drug Developmentmanufacturingand Commercialization Efforts Smpa Focuses On Innovative Therapies For Unmet Medical Needs In Areas Such As Oncologywomenae S Healthurologyrare Diseasesneurologypsychiatryand Cell Gene Therapiesthe Company Drives Research And Development For High Need Therapeutic Areasmanufactures Specialized Treatments Including Biologicsand Commercializes Therapies Through Integrated Marketing And Distribution Channelsits Portfolio Features Fda Approved Therapies Like Orgovyxafor Advanced Prostate Cancer And Myfembreeafor Uterine Fibroids And Endometriosisamong Otherssmpa Aims To Improve The Quality Of Life For Patients And Caregiversparticularly In Niche Therapeutic Areas
